Section Arrow
GOVX.NASDAQ
- GeoVax Labs
Quotes are at least 15-min delayed:2025/07/21 07:11 EDT
Pre Market
Last
 0.77
+0.005 (+0.65%)
Bid
0.7665
Ask
0.78
High 0.8 
Low 0.7512 
Volume 10016 
Regular Hours
Last
 0.765
+0.0344 (+4.71%)
Day High 
0.778 
Prev. Close
0.7306 
1-M High
1.23 
Volume 
1.01M 
Bid
0.7665
Ask
0.78
Day Low
0.73 
Open
0.74 
1-M Low
0.43 
Market Cap 
18.38M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.65 
20-SMA 0.74 
50-SMA 0.92 
52-W High 11.18 
52-W Low 0.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.80/-0.82
Enterprise Value
18.40M
Balance Sheet
Book Value Per Share
0.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.95M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.04 -0.24 -10.53%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 12.6 -1.475 -10.48%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0477 0 0.00%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.195 +0.355 +6.08%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.24 +0.32 +5.41%
Quotes are at least 15-min delayed:2025/07/21 07:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing humanclinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.